摘要
1例46岁女性患者,因术后颅内感染静脉滴注哌拉西林钠他唑巴坦钠4.5 g,1次/8 h。用药第13、15天外周血白细胞计数从用药前的10.61×109/L分别降至1.79×109/L和1.00×109/L。立即换用其他抗菌药物,同时给予重组人粒细胞巨噬细胞集落刺激因子(rhGM-CSF)150μg皮下注射,1次/d。改变治疗后4 d,血白细胞计数升至6.95×109/L。改变治疗后6 d脑脊液白细胞数由首次用药后15 d的8×106/L升至56×106/L,再次给予哌拉西林钠他唑巴坦钠4.5 g静脉滴注,1次/8 h,rhGM-CSF剂量未变。用药6 d颅内感染治愈,遂停用抗菌药物。治疗第2、5天白细胞计数分别为2.67×109/L和1.65×109/L。第8天停用rhGM-CSF后为5.75×109/L,第15天为4.56×109/L。
A 46-year-old woman received an IV infusion of piperacillin sodium/tazobactam sodium 4. 5g every 8 hours for postoperative intracranial infection . Her WBC count decreased from I0.61 × 109/L before treatment to 1.79 × 109/L on day 13 of treatment and 1.00 × 109/L on day 15 of treatment, respectively. Piperaciflin/tazobactam was withdrawn immediately and switched to other antibacterial drugs, and then hypodermic recombinant human granulocyte macrophage colony stimulating factor （rhGM-CSF） 150 μg once daily was given. Four days after the treatment changes, her WBC count increased to 6.95 ×109/L. Six days after the treatment ehanges, her cerebrospinal fluid WBC count increased from 8 ×106/L（ 15 days after the first administration） to 56 × 106/L, she was readministered an IV infusion of piperaeillin/tazobactam 4.5 g every 8 hours and her rhGM-CSF dosage remained unchanged. After a 6-day treatment, her intracranial infection was cured, antibacterial drugs were stopped. On days 2 and 5 of treatment, her WBC count was 2.67 × 109/L and 1.65 × 109/L, respectively. On day 8, rhGM-CS was withdrawn and WBC count was 5.75 × 109/L. On day 15, WBC count was 4.56 × 109/L.
出处
《药物不良反应杂志》
2012年第5期308-309,共2页
Adverse Drug Reactions Journal
基金
甘肃省自然科学基金(1107RJZA238)
